MA: Less access for Australians the 'only likely outcome' of US proposal

New Stories

• Tour de Cure backs further development of Noxopharm's preclinical brain cancer candidate

  April 24, 2024 - - Latest News

• Novartis nominates ex-BMS chief executive as its new chair

  April 24, 2024 - - Latest News

• 'The Pharmac system again, over about 33 years old, hasn’t really changed and evolved'

  April 24, 2024 - - Latest News

• AusBiotech appoints experienced Sanofi leader as its new chief executive

  April 23, 2024 - - Latest News

• Should principles such as 'equity' and 'opportunity cost' be applied consistently or not at all?

  April 23, 2024 - - Latest News

• Rare Cancers Australia welcomes new appointments to its board of directors

  April 23, 2024 - - Latest News

• BMS and Australian venture capital firm back immunotherapy company Pathios Therapeutics

  April 23, 2024 - - Latest News